Abstract: Despite the heightened interest in developing biomarkers predicting treatment response that are used to optimize patient treatment decisions, there has been relatively little development of statistical methodology to evaluate these markers. There is currently no unified statistical framework for marker evaluation. This paper proposes a suite of descriptive and inferential methods designed to evaluate individual markers and to compare candidate markers. An R software package has been developed which implements these methods. Their utility is illustrated in the breast cancer treatment context, where candidate markers are evaluated for their ability to identify a subset of women who do not benefit from adjuvant chemotherapy and can therefore avoid its toxicity.
Introduction
There is an enormous amount of research effort being devoted to discovering and evaluating markers that can predict a patient's chance of responding to treatment. A December, 2013 PubMed search identified 8, 198 papers evaluating such markers over the last 2 years alone. Treatment selection markers, sometimes called "predictive" [1] or "prescriptive" [2] markers, have the potential to improve patient outcomes and reduce medical costs by allowing treatment provision to be restricted to those subjects most likely to benefit, and avoiding treatment in those only likely to suffer its side effects and other costs.
Methods for evaluating treatment selection markers are much less well developed than for markers used to diagnose disease or predict risk under a single treatment. In the medical literature, the most common approach to marker evaluation is to test for a statistical interaction between the marker and treatment in the context of a randomized and controlled trial (RCT; see Coates et al. [3] , Busch et al. [4] , and Malmstrom et al. and NCBTSG [5] for some recent examples). However this approach has limitations in that it does not provide a clinically relevant measure of the benefit of using the marker to select treatment and does not facilitate comparing candidate markers [6] . Moreover, the scale and magnitude of the interaction coefficient will depend on the form of the regression model used to test for interaction and on the other covariates included in this model [7] .
There is a growing literature on statistical methods for evaluating treatment selection markers. A number of papers have focused on descriptive analysis, specifically on modeling the treatment effect as a function of marker [8] [9] [10] [11] [12] . In general, these approaches are not well-suited to the task of comparing candidate markers. Other papers have proposed individual measures for evaluating markers [6, 7, [13] [14] [15] [16] , some of which we adopt as part of our analytic approach as described below. Still others have focused on the specific problem of optimizing marker combinations for treatment selection [17] [18] [19] [20] [21] [22] . A complete framework for marker evaluation, on a par with those developed for evaluating markers for classification [23, 24] or risk prediction [25] , is still forthcoming.
In this paper, we lay out a comprehensive approach to evaluate markers for treatment selection. We propose tools for descriptive analysis and summary measures for formal evaluation and comparison of markers. The descriptives are conceptually similar to those of Bonetti and Gelber [8] , Royston and Sauerbrei [9] , Cai et al. [10] , but we scale markers to the percentile scale to facilitate making comparisons. Our preferred global summary measure is the same as or closely related to that advocated by Song and Pepe [13] , Brinkley et al. [16] , Janes et al. [6] , Gunter et al. [19] , Qian and Murphy [20] , McKeague and Qian [21] , and Zhang et al. [22] , a component of which was described by Zhao et al. [12] and Baker and Kramer [14] . We also propose several novel measures of treatment selection performance, motivated by existing methodology for evaluating markers for predicting outcome under a single treatment, i.e. for risk prediction. We develop methods for estimation and inference that apply to data from a randomized controlled trial comparing two treatment options where the marker is measured at baseline on all or a stratified case-control sample of trial participants. For illustration, we consider the breast cancer treatment context where candidate markers are evaluated for their utility in identifying a subset of women who do not benefit from adjuvant chemotherapy. Appendices include the results of a small-scale simulation study that evaluates the performance of the methods in finite samples and a description of the R package we have written that implements these methods.
Setting and notation
Suppose that the task is to decide between two treatment options, referred to as "treatment" (T ¼ 1) and "no treatment" (T ¼ 0). The clinical outcome of interest, D, is a binary indicator of a bad event within a specific time-frame following treatment provision; we refer to this outcome as an "adverse event" or "event". The outcome D is thought to capture all potential impacts of treatment, so that any decrease in the rate of events justifies treatment; a generalization is discussed in Section 6.1. To achieve this, D may be chosen to represent a composite outcome such as an indicator of treatment-associated toxicity or death. We assume that the marginal treatment effect ρ 0 À ρ 1 ;PðD ¼ 1 j T ¼ 0Þ À PðD ¼ 1 j T ¼ 1Þ is positive, so that the default approach is to treat all subjects. The question is whether a marker, Y, if measured prior to treatment provision, is useful for identifying a subset of subjects who can avoid treatment. Note that the scenario where the marginal treatment effect is negative (or zero) and Y identifies a subset of subjects who benefit from treatment can be handled by simply reversing the treatment labels.
We focus on the ideal setting for evaluating treatment efficacy, an RCT comparing T ¼ 1 with T ¼ 0. By necessity, this must be a relatively large trial; it is well-known that large sample sizes are generally needed to detect statistical interactions. We assume to begin that Y is continuous and measured at baseline on all trial participants. We generalize our methods to case-control sampling from within an RCT in Section 6.2.
Motivating context
We illustrate our methods in the breast cancer treatment context. Women diagnosed with estrogen-receptorpositive and node-positive breast cancer are typically treated with both hormone therapy (e.g. tamoxifen) and adjuvant chemotherapy following surgery. This is despite the fact that it is generally well-accepted in the clinical community that only a subset of these women actually benefit from the adjuvant chemotherapy, and the remaining women suffer its toxic side effects, not to mention the burden and cost of unnecessary treatment [26] . A high public health priority is to identify biomarkers that can be used to predict which women are and are not likely to benefit from the adjuvant chemotherapy [27] . The Oncotype DX recurrence score is an example of a biomarker that is currently being used in clinical practice for this purpose. This marker is a proprietary combination of 21 genes whose expression levels are measured in the tumor tissue obtained at surgery [28] [29] [30] . The marker has been shown to have value for identifying a subset of women who are unlikely to benefit from chemotherapy [28, 29, and 30] .
To illustrate our methods, we simulated a marker, Y 1 , with the same performance as Oncotype DX in the SWOG SS8814 trial which evaluated adjuvant chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil) given before tamoxifen for treating post-menopausal women with estrogen-receptor-positive, nodepositive breast cancer [28, 31] . We also simulated another marker, Y 2 , which we will demonstrate is a much stronger marker. Both markers Y 1 and Y 2 are measured at baseline for 1,000 participants randomized with equal probability to tamoxifen alone (T ¼ 0) or tamoxifen plus chemotherapy (T ¼ 1). The outcome, D, is breast cancer recurrence or death within 5 years of randomization, and the marginal treatment effect is 
for Y 1 the model coefficients are chosen to mimic the performance of the Oncotype DX recurrence score [28] . Methods for simulating the data are described in the Appendix.
Methods for evaluating individual markers

Treatment rule
Given that the task is to decide between treatment and no treatment for each individual subject, it is sensible and common to define a binary rule for assigning treatment on the basis of marker value. Let
YÞ denote the absolute treatment effect given marker value Y. The rule do not treat if ΔðYÞ < 0 can be shown to be optimal in the sense that it minimizes the population event rate [16, 22, 32] . Some of the marker performance measures we consider evaluate the properties of this rule; other performance measures do not depend on specification of a treatment rule. We refer to subjects with ΔðYÞ < 0 as "marker-negatives" and ΔðYÞ > 0 as "marker-positives". More general treatment rules are considered in Section 6.1.
Descriptives
For descriptive analysis, it is useful to display the distribution of risk of the event as a function of the marker under each treatment. We plot "risk curves" PðD ¼ 1 j T ¼ 1; YÞ and PðD ¼ 1 j T ¼ 0; YÞ vs marker percentile FðYÞ, where F is the cumulative distribution function (CDF) of Y [6] . Figure 1 shows the risk curves for the Oncotype-DX-like marker, Y 1 , and the much better marker, Y 2 . From these one can visually assess the variability in response on each treatment as a function of marker value. One can also determine the proportion of subjects with negative treatment effects who can avoid chemotherapy, 46% for Y 1 vs 38% for Y 2 .
Another informative display is the distribution of treatment effect, as summarized by ΔðYÞ vs F Δ ðΔðYÞÞ where F Δ is the CDF of ΔðYÞ [7] . The example shown in Figure 2 reveals that Y 2 has much greater variation in marker-specific treatment effect than does Y 1 . For Y 2 a greater proportion of marker-specific treatment effects are extreme, whereas for Y 1 the range is smaller and most treatment effects are near the average of ρ 0 À ρ 1 ¼ 0:03. 
Summary measures
The following are useful measures for summarizing marker performance that depend on specification of the treatment rule: -Average benefit of no treatment among marker-negatives,
-Average benefit of treatment among marker-positives,
-Proportion marker-negative, P neg ¼ PðΔðYÞ < 0Þ -Decrease in population event rate under marker-based treatment,
where we define PðD ¼ 1 j T; ΔðYÞ < 0Þ ¼ 0 if PðΔðYÞ < 0Þ ¼ 0. The measure Θ, or a variation on it, has been advocated by many as a global measure of marker performance [2, 6, 13, 16, 21, 22] . Θ varies between 0 and ρ 1 . The minimum value of 0 corresponds to an entirely useless marker with constant marker-specific treatment effect,
The constituents of Θ, namely B neg and P neg , are helpful for dissecting the impact of the marker. The measures B neg and B pos inform on the average benefit of the treatment policies recommended to marker- negatives and marker-positives, respectively. B neg itself has been advocated by some as a measure of marker performance [12, 14] , but clearly cannot be interpreted in isolation as it can be made arbitrarily large by making the marker-negative subgroup more extreme; i.e. the size of the subgroup (P neg ) is also relevant.
We also consider two marker performance measures that do not depend on specification of a treatment rule:
-Total gain, the area between the treatment effect curve and the marginal treatment effect,
The V Δ and TG measures suffer because of lack of clinical interpretation, but have the advantage of being independent of treatment rule and potentially form the basis for more efficient comparisons of markers. These measures are extensions of those used to evaluate markers for predicting risk of the event under a single treatment, rather than the treatment effect. Table 1 contains estimates of V Δ and TG measures for markers Y 1 and Y 2 in the breast cancer example. Focusing on Y 2 , we see that the population impact of Y 2 -based treatment is a 10% reduction in the 5-year recurrence or death rate; this is a consequence of 38% of subjects avoiding adjuvant chemotherapy and a 26% reduction in the event rate due to avoiding chemotherapy in this subgroup. Among marker-positives, chemotherapy decreases the event rate by 21% on average. Less interpretable, but somewhat useful for global marker comparisons, are the values of V Δ ¼ 0:08 and TG ¼ 0:22.
Estimation and inference
Our proposed estimation and inference methods build on methodology developed for risk prediction [33] [34] [35] . This section overviews these approaches that are evaluated in a small-scale simulation study described in the Appendix. An R software package that implements these methods is also described in the Appendix.
Estimation
Given data consisting of i.i.d copies of ðY i ; T i ; D i Þ, i ¼ 1; . . . ; N, the first step in estimation is to fit a model for risk as a function of T and Y. We use a general linear regression risk model with an interaction between T and Y,
Typically we let g be the logit function because of its advantages with case-control data (see Section 6.2) and because we have found logistic regression to be remarkably robust to model mis-specification. We note that the general linear model (1) is flexible in that the marker Y can itself be a transformed marker value. The risk and treatment effect estimates that result from fitting from this model are written Pointwise α-level horizontal CIs inform about the variability in the proportion of participants at or below a given risk level; we obtain these using the percentile bootstrap method. The estimated treatment effect curve is b ΔðYÞ
Here pointwise horizontal CIs capture the variability in the estimated proportion of individuals with treatment effects below a certain value.
For the summary measures that depend on treatment rule, we consider both "empirical" and "modelbased" estimators. An empirical estimator uses the estimated risk model (1) P denotes an empirical probability estimate and b E denotes an empirical mean:
The treatment-rule-independent summary measures are estimated using the following model-based estimators:
whereρ 0 andρ 1 are empirical estimates of PðD ¼ 1 j T ¼ 0Þ and PðD ¼ 1 j T ¼ 1Þ, respectively. CIs for each summary measure are obtained using the percentile bootstrap.
Hypothesis testing
Testing whether a marker has any performance for treatment selection is of interest for two reasons. First, this is a logical first step in marker evaluation. Second, the performance measures described above may have poor statistical properties at and near the null of no marker performance. This is similar to problems that have been identified with measures of risk prediction model performance [36] [37] [38] [39] [40] [41] 
Other approaches have been proposed for testing the null of no marker performance [42, 43] ; optimizing this test is not our focus.
For the unbounded markers Y 1 and Y 2 in our breast cancer example, H 0 is rejected with p ¼ 0:005 and p < 0:0001, respectively.
Calibration assessment
Assessing model calibration is a fundamental step in marker evaluation. We rely on standard methods for visualizing and testing goodness of fit for the risk model (1) and extend these methods to assess calibration of the treatment effect model.
Since patients are provided risk estimates under both treatment options, first we assess the fit of the risk model separately in the two treatment groups. Specifically, we define a well-calibrated model to be one for which PðD ¼ 1 j T ¼ 0; Risk 0 ðYÞ ¼ rÞ % r and PðD ¼ 1 j T ¼ Figure 3 .
To formally assess model calibration, a traditional Hosmer-Lemeshow goodness of fit test [44] can be applied separately to the two treatment groups. Specifically, for group T ¼ t the test statistic
where N tg is the number of participants in the gth group for T ¼ t, is compared to a χ 2 distribution with G À 2 degrees of freedom. Another aspect of calibration is the extent to which the treatment effect model fits well. We want to ensure that PðD ¼ 1 j T ¼ 0; ΔðYÞ ¼ δÞ À PðD ¼ 1 j T ¼ 1; ΔðYÞ ¼ δÞ % δ. Following the approach above, we split the data into G evenly-sized groups based on b
ΔðYÞ and calculate the average predicted treatment effect, Δ g ðYÞ, and observed treatment effect, b
We plot the treatment effect curve and overlay the G observed treatment effect values as shown in Figure 3 . Based on Figure 3 , we see that the risk and treatment effect models for Y 1 and Y 2 in the breast cancer example are well-calibrated; the Hosmer-Lemeshow test statistics are 4.5 (p ¼ 0:81) and 8.9 (p ¼ 0:35) given T ¼ 0 and 5.0 (p ¼ 0:76) and 2.9 (p ¼ 0:94) given T ¼ 1. The Risk 0 ðY 2 Þ and ΔðY 1 Þ curves suggest some evidence of poor calibration, which in our simulated data setting is attributable to sampling variability in the observed risks that are calculated using 50 observations each.
Comparing markers
The descriptives and summary measures proposed herein form the basis for comparing candidate markers. We assume that the two markers, Y 1 and Y 2 , are measured on the same subjects, i.e. that the data are paired. With unpaired data, the analyses described above can be applied to each individual dataset and inferences can be drawn easily given that the estimated summary measures are statistically independent. For drawing inference about the relative performance of two markers given paired data, CIs for the differences in performance measures and hypothesis tests of whether these differ from zero are informative. We fit separate models for PðD ¼ 1 j T; Y 1 Þ and PðD ¼ 1 j T; Y 2 Þ, use these to estimate performance measures for Y 1 and Y 2 , respectively, and bootstrap the differences in estimated performance measures. While global measures of marker performance such as Θ, V Δ , and TG are appropriate as the basis for formal marker comparisons, differences in the other summary measures inform about the nature of the difference between markers. We advocate Θ as the primary measure on which to base marker comparisons, given its clear clinical relevance and interpretation.
The results of the comparative analysis for the breast cancer example are shown in Table 1 . We can see clearly that Y 2 has uniformly better performance than Y 1 , with an estimated 10% vs 1% reduction in the 5-year recurrence or death rate. Despite the fact that there are estimated to be fewer marker-negative subjects based on Y 2 (38% vs 46%), there is a much greater estimated benefit of no chemotherapy among Y 2 -markernegatives (26% vs 2% reduction in the 5-year recurrence or death rate). In general the variation in treatment effect is larger for Y 2 .
Extensions
General treatment rules
In some settings there may be additional consequences of treatment that are not captured in the outcome, for example treatment-associated toxicities. This means that a treatment effect somewhat above zero may still warrant no treatment because it is offset by the other consequences of treatment. In these settings the optimal treatment rule can be shown to be do not treat if ΔðYÞ < δ; where δ > 0 is equal to the burden of treatment relative to that of the adverse event [15, 32] . The performance measures described above generalize naturally to this treatment rule:
Note that the V Δ and TG measures do not require specification of a treatment rule. Further generalization to the setting where the burden of treatment and/or of the adverse event varies between individuals, perhaps as a function of Y, is described by Janes et al. [32] .
Case-control sampling
The methods described above apply to the setting where the marker is measured at baseline on all RCT participants. However when the outcome D is rare, case-control sampling from within the RCT is a wellknown efficient alternative that recovers much of the information contained in the entire trial population. This section extends the methods to the setting where the data consist of a case-control sample from the RCT, or a case-control sample stratified on treatment assignment, T. We consider case-control designs that sample all or a fixed proportion of the cases in the RCT, as well as a number of controls (perhaps stratified on T) that is a fixed multiple of the number of cases sampled. Consider first unstratified case-control sampling. Suppose N D and N D cases and controls occur in the trial "cohort" (N ¼ N D þ N D ) . The case-control sample consists of a sample of n D ¼ f Á N D cases and n D ¼ k Á n D controls, where f 2 ð0; 1 and the control:case ratio k is an integer. Commonly all the cases are sampled (f ¼ 1), and 1-5 controls are sampled per case. Alternatively f may be set to a value less than 1 for a common event or when budget concerns or sample availability limit the number of cases that can be sampled; in these instances we assume that selection into the case-control sample is completely random conditional on D ¼ 1.
Let S ¼ 1 be an indicator of selection into the case-control sample. Given the case-control data, the task is to correct the estimates of PðD ¼ 1 j T; Y; S ¼ 1Þ and PðΔðYÞ < δ j S ¼ 1Þ for the case-control sampling. Suppose that an estimate of PðD ¼ 1Þ is available from the cohort. Using Bayes' Theorem and the assumption of case-control sampling that PðS ¼ 1 j T; Y; DÞ ¼ PðS ¼ 1 j DÞ we obtain the following identity which is used to correct the estimates of PðD ¼ 1 j T; Y; S ¼ 1Þ for the case-control sampling:
This result was originally cited by Prentice and Pyke [45] as the rationale for using logistic regression to model risk with case-control data. Note that PðD ¼ 1 j T; Y; S ¼ 1Þ can be estimated using the logistic regression risk model (1) fit to the case-control data, PðD ¼ 1Þ can be estimated from the trial cohort, and PðD ¼ 1 j S ¼ 1Þ estimated from the case-control data. The distribution of ΔðYÞ, or equivalently of Y itself, can be estimated in the cases and controls in the case-control data and corrected to the cohort distribution via
where superscript cc denotes estimation in the case-control sample and D and D subscripts denote case and control subsets.
We use a modified bootstrapping procedure for case-control data. To reproduce the variability in the cohort from which the case-control study is sampled, we first sample
controls from the subjects in the casecontrol study. The estimation procedure is then performed in each bootstrap sample, and quantiles of the bootstrap distribution are used to characterize uncertainty.
Case-control sampling stratified on treatment assignment can also be accommodated. Here we assume a cohort with ðN D0 ; N D0 ; N D1 ; N D1 Þ subjects in each D Â T stratum. The case-control sample consists of n D0 ¼ f 0 Á N D0 and n D1 ¼ f 1 Á N D1 cases for fixed proportions f 0 and f 1 in the two treatment groups, and n D0 ¼ k 0 Á n D0 and n D1 ¼ k 1 Á n D1 controls for fixed control:case ratios k 0 and k 1 . Assume that estimates of PðD ¼ 1 j T ¼ 0Þ, PðD ¼ 1 j T ¼ 1Þ, and PðT ¼ 1Þ are available from the cohort. A similar identity can be exploited for estimation:
The distribution of ΔðYÞ combines empirical CDFs from the four D Â T strata:
. The stratified case-control sample is then sampled from the case and control subsets.
For calibration assessment, we plot observed and predicted risks and treatment effects as described in Section 4.5, where all are corrected for the biased sampling as described above. We also implement a variation on the Hosmer-Lemeshow test applied to case-control data (expression (7) of Huang and Pepe [33] ).
Discussion
This paper proposes a statistical framework for evaluating a candidate treatment selection marker and for comparing two markers. Estimation and inference techniques are described for the setting where the marker or markers are measured on all or a treatment-stratified case-control sample of participants in a randomized, controlled trial. An R software package was developed which implements these methods. Developing a solid framework for evaluating and comparing markers is fundamental for accomplishing more sophisticated tasks such as combining markers, accounting for covariates, and assessing the improvement in performance associated with adding a new marker to a set of established markers.
Our approach to marker evaluation also applies when the marker is discrete. In addition, it can be applied when there are multiple markers and interest lies in evaluating their combination;
YÞ is the combination of interest and the measures described here can be used to summarize the performance of this combination.
This work extends existing approaches for evaluating markers for risk prediction [25, 35, 46] . It also unifies existing methodology for evaluating treatment selection markers. In particular, our preferred marker performance measure has been advocated by Song and Pepe [13] , Brinkley et al. [16] , Janes et al. [6] , Gunter et al. [19] , Qian and Murphy [20] , McKeague and Qian [21] , and Zhang et al. [22] .
There are challenges with making inference about the performance measures we propose, similar to problems that have been identified with measures of risk prediction model performance including the area under the ROC curve [36, [38] [39] [40] , the integrated discrimination index [37] , and the net reclassification index [41] . The problems may arise when the sample size is modest and marker performance is weak. In particular for the Oncotype DX example, given that the marker is weak and the primary study evaluating its performance by Albain et al. [28] included just 367 women, our simulation results suggest that the resultant estimate of Θ is likely an over-estimate and that the CI may be conservative. For this reason, we propose testing for non-null marker performance prior to estimating the magnitude of performance. This approach performed reasonably well in our simulation studies, but improved approaches to inference, for the treatment selection as well as risk prediction problem, merit investigation.
The methods described here can and should be extended to accommodate other types of outcomes. Extension to continuous or count outcomes is straightforward. Specifically, after replacing PðD ¼ 1Þ with EðDÞ and using a risk model appropriate to the scale of the outcome, e.g. a linear or log-linear model for a continuous outcome, the analysis proceeds as above. The conceptual framework also applies to time-to-event outcomes, with the task being to predict risk of the outcome by a specified landmark time.
The methods may also be generalized to an observational study setting, or to a setting where data on the two treatments come from two different studies -perhaps historical data are paired with a single-arm trial of T ¼ 1. However, the usual concerns about measured and unmeasured confounding in estimating the treatment effect apply. In this setting, an analyst would be well-advised to stratify on variables that are potentially associated with treatment provision and outcome. More generally, methods for adjusting for covariates in the evaluation of marker performance warrant further research.
Simulation studies
This section describes a small-scale simulation study that was performed to evaluate the statistical performance of our methods. Data were simulated to reflect the breast cancer RCT example, with T an indicator of chemotherapy in addition to tamoxifen, randomly assigned to half of study participants. Rates of 5-year breast cancer recurrence or death (D) were set to 21% and 24% with and without chemotherapy, respectively, as in SWOG SS8814 [28] . We explored the performance of the methods for a weak marker and a strong marker, both of which relate to D via the linear logistic model (1). The weak marker, Y 1 , mimics the performance of the Oncotype DX recurrence score as seen in Albain et al. [28] ; ffiffiffi ffi Y p 1 is normally distributed with mean 4.8 and standard deviation 1.8. The strong marker, Y 2 , follows a standard normal distribution. We used the following procedure to simulate data. We denote the potential outcomes with and without treatment by Dð1Þ and Dð0Þ. We specified models for PðDð0Þ; Dð1Þ j Y j Þ, j ¼ 1; 2 that induce marginal linear logistic models as in eq. (1). Specifically, we assumed
where k ensures that ð PðDð0Þ ¼ 0; 
These models fully specify the joint distribution of ðDð0Þ; Dð1ÞÞ given Y j , j ¼ 1; 2. Note that our measures and estimators depend only on the marginal distributions PðDð0Þ ¼ 1 j Y j Þ and PðDð1Þ ¼ 1 j Y j Þ, j ¼ 1; 2, and hence are invariant to the choice of joint distribution. Next, we used Bayes' Theorem to calculate PðY j j Dð0Þ; Dð1ÞÞ, j ¼ 1; 2. We first simulated pairs of potential outcomes ðDð0Þ; Dð1ÞÞ from the multinomial distribution induced by eqs (1a) and (2a). Then we simulated independent Y 1 and Y 2 from PðY j j Dð0Þ; Dð1ÞÞ, j ¼ 1; 2. Treatment assignment, T, was generated independent of potential outcomes and marker values. The observed outcome D was defined as D ¼ Dð1ÞT þ Dð0Þð1 À TÞ. True values for the marker performance measures were calculated as the average parameter estimates, using the true risk function (1), across 10 very large datasets (N ¼ 20; 000; 000). We explore the bias and variance of the parameter estimates and false-coverage probabilities of the bootstrap percentile CIs for sample sizes ranging from N ¼ 250 to N ¼ 5; 000. A total of 5,000 simulations were performed for each sample size. To explore the impact of our proposed pre-testing strategy, whereby the parameters are not estimated if H 0 : Θ ¼ 0 is not rejected, we evaluate the parameter estimates and CIs marginally and conditionally. Marginal means of parameter estimates include all estimates regardless of H 0 rejection, and conditional means are computed only among datasets where H 0 is rejected. The following probabilities of false coverage of nominal 95% CIs are evaluated: 1. Marginal probability of false coverage, where CIs are calculated regardless of H 0 rejection; 2. Conditional probability of false coverage, computed only among datasets where H 0 is rejected; and 3. Probability of rejecting H 0 and the CI not covering the true value, termed the "false conclusion probability" [47] .
Strong marker
The results for the strong marker are contained in Tables A.1-A.3 . For this marker, we see that the estimates and CIs have uniformly good performance. Marginal bias is small and false coverage is near nominal; the pre-testing has no impact because of the 100% power to reject H 0 for this marker. There is minimal increase in variance due to using empirical vs model-based estimators.
Weak marker
The results for the weak marker are contained in Tables A. 4-A.6 . With N ¼ 250 or 500, conditional on rejecting H 0 the bias in parameter estimates and false coverage of CIs can be substantial; however rejecting H 0 is unlikely with power 21% or 36%. Marginally, mean parameter estimates are substantially closer to their true values and false-coverage probabilities are generally near nominal. False conclusion probabilities are less than nominal but sometimes substantially below 0.05 indicating over-conservatism. With Notes: For Θ, B neg , and B pos , results are shown for both empirical and model-based estimators. Percentile bootstrap CIs are evaluated using: marginal false coverage, the proportion of CIs that do not cover the true value regardless of H 0 rejection; conditional false coverage, the proportion of CIs that do not cover the true value among datasets where H 0 is rejected; and false conclusion probability, the proportion of datasets where H 0 is rejected and the CI does not cover the true value. The probability of rejecting H 0 : Θ ¼ 0 is also shown. Notes: For Θ, B neg , and B pos , results are shown for both empirical and model-based estimators. Percentile bootstrap CIs are evaluated using: marginal false coverage, the proportion of CIs that do not cover the true value regardless of H 0 rejection; conditional false coverage, the proportion of CIs that do not cover the true value among datasets where H 0 is rejected; and false conclusion probability, the proportion of datasets where H 0 is rejected and the CI does not cover the true value. The probability of rejecting H 0 : Θ ¼ 0 is also shown.
N ¼ 1; 000 or 5,000, conditional and marginal bias is generally small and false-coverage probabilities are near or below nominal. False conclusion probabilities continue to be less than nominal. This example demonstrates that, for markers with near-null performance, substantial sample sizes are required for accurate inference. We also see that with smaller sample sizes there can be a substantial increase in variability associated with use of empirical vs model-based estimators.
Software
We developed a package in the open-source software R called TreatmentSelection that implements our methods for evaluating individual markers and for comparing markers. The software is available at http:// labs.fhcrc.org/janes/index.html. The following functions are included.
-trtsel creates a treatment selection object -eval.trtsel evaluates a treatment selection object, producing estimates and CIs for the summary measures described in Section 4.3 -plot.trtsel plots a treatment selection object, producing risk curves and the treatment effect curve described in Section 4.2 -calibrate.trtsel assesses the calibration of a fitted risk model and treatment effect model using methods described in Section 4.5 -compare.trtsel compares two markers using methods described in Section 5
Case-control and treatment-stratified case-control samplings are accommodated.
Here we illustrate use of the code by showing how the results shown in Figures 1-3 and Treatment selection objects are created and displayed for Y1 and Y2 using the commands > trtsel.Y1 <-trtsel(event = "event", trt = "trt", marker = "Y1", data = tsdata, study. > trtsel.Y2 <-trtsel(event = "event", trt = "trt", marker = "Y2", data = tsdata, study.design="randomized cohort") > trtsel.Y2 Study design: randomized cohort The descriptives shown in Figure 1 are produced using > plot.trtsel(trtsel.Y1, main = "Yl: Oncotype-DX-like marker", bootstraps = 500, trt.names=c("chemo.","no chemo.")) > plot.trtsel(trtsel.Y2, main = "Y2: Strong marker", bootstraps = 500, trt.names=c("chemo.","no chemo.")) The summary measure estimates and CIs shown in Table 1 The markers are compared based on summary measures, and visually (as in Figure 2 ) using > mycompare <-compare.trtsel(trtsell = trtsel.Y1, trtsel2 = trtsel.Y2, bootstraps = 500, plot = TRUE, main = "", marker.names=c("Yl","Y2"))
